Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study

Inflammatory Bowel Disease

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Therap Adv Gastroenterol.

Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M

doi: 10.1177/1756284819895217.

COMMENTED

Inflammatory Bowel Disease

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis

Int J Colorectal Dis.

Novello M, Stocchi L, Holubar S, Shawki S, Lipman J, Gorgun E, Hull T, Steele SR

doi: 10.1007/s00384-018-3212-6.

COMMENTED

Inflammatory Bowel Disease

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

J Crohns Colitis.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A, GETAID.

doi: 10.1093/ecco-jcc/jjz088.

Inflammatory Bowel Disease

Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics

J Crohns Colitis.

Novello M, Stocchi L, Steele SR, Holubar SD, Duraes LC, Kessler H, Shawki S, Hull LT

doi: 10.1093/ecco-jcc/jjz129.

Inflammatory Bowel Disease

Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: the NSQIP Surgical Cohort

J Crohns Colitis.

Nguyen GC, Du L, Chong RY, Jackson TD

doi: 10.1093/ecco-jcc/jjz083.

Inflammatory Bowel Disease

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study

doi: 10.1093/ecco-jcc/jjy183.

RECOMMENDED

Inflammatory Bowel Disease

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Inflamm Bowel Dis.

Biancone L, Armuzzi A, Scribano ML, Castiglione F, D'incà R, Orlando A, Papi C, Daperno M, Vecchi M, Riegler G, Fries W, Alvisi P, Meucci G, Mocciaro F, Rogai F, Festa S, Guidi L, Testa A, Spina L, Renna S, Viola A, Patturelli M, Di Mitri R, Frankovic I, Calabrese E, Petruzziello C, De Cristofaro E, Sena G, Ruffa A, Neri B, Rossi A, Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).

doi: 10.1093/ibd/izz155.

Inflammatory Bowel Disease

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Inflamm Bowel Dis.

Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM

doi: 10.1093/ibd/izz001.

COMMENTED

Inflammatory Bowel Disease

Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort

★ 1 Recommended and commented by Prof. Dr Stephan Vavricka, Faculty Member

United European Gastroenterol J

Greuter T, Porchet F, Braga-Neto MB, Rossel JB, Biedermann L, Schreiner P, Scharl M, Schoepfer AM, Safroneeva E, Straumann A, Rogler G, Vavricka SR

doi: 10.1177/2050640620954556

Related content

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study

Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study

Case-matched comparison of postoperative outcomes following surgery for inflammatory bowel disease after exposure to vedolizumab vs. other biologics

Hypoalbuminaemia and Postoperative Outcomes in Inflammatory Bowel Disease: the NSQIP Surgical Cohort

Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study

Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study

Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy

Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort